Multiple Myeloma: Clinical Updates from the American Society of Hematology Annual Meeting 2016

The benefit from early therapeutic intervention in patients with high-risk smoldering multiple myeloma (SMM) is always a matter of great importance for the myeloma community. In a phase 2 study, 39 patients with high-risk SMM (median age 62 years) were given weekly elotuzumab (10 mg/kg) on days 1, 8, 15, and 22 for the first two 28-day cycles, in combination with lenalidomide on days 1-21 and dexamethasone 40 mg on days 1, 8 and 15 (Arm A). An initial cohort of patients were randomized to receive lower dose of dexamethasone along with elotuzumab and lenalidomide (Arm B) based on the following stratification factors: age>65 years and high-risk cytogenetics based on t(4:14), t(14:16), 17p deletion or p53 mutation, and +1q amplification.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research